Increased serum B‐cell maturation antigen levels evaluated with an Elecsys‐based serum B‐cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma

Ähnliche Einträge

• Thrombotic and bleeding complications in patients with AL amyloidosis
  von: Despina Fotiou, et al.
  Veröffentlicht: (2024)
• ciRS‐7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma
  von: Maria Papatsirou, et al.
  Veröffentlicht: (2024)
• Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution
  von: Meletios A. Dimopoulos, et al.
  Veröffentlicht: (2025)
• Effects of Exercise Training on the Bone Marrow Immune Microenvironment and Minimal Residual Disease in Multiple Myeloma Patients Following First‐Line Treatment
  von: Polyxeni Spiliopoulou, et al.
  Veröffentlicht: (2025)
• Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centre
  von: Maria Gavriatopoulou, et al.
  Veröffentlicht: (2026)